In 498 patients in China with EGFR-mutated advanced NSCLC progressing after EGFR-TKI therapy, the HER3-directed antibody-drug conjugate ruzaltatug rezetecan improved PFS vs platinum–pemetrexed (median 8·3 vs 5·4 months; HR 0·47) at interim analysis.
RCTn = 498
Xu et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China